Based upon the significant increase of S100A2 mRNA levels with each ligand alone and the synergistic increase with combination therapy, we performed additional experiments with S100A2 to define its role in mediating the effects of combination rexinoid/TZD treatment in melanoma cells. This evidence concerns the gene S100A2 and melanoma.